ARDSLEY, N.Y.--(BUSINESS WIRE)--
Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that Ron Cohen, M.D.,
Acorda's President and CEO, will present at the 37th Annual
J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January
9 at 8:00am PST / 5:00am EST.
A live audio webcast of the presentation can be accessed under “Investor
Events” in the Investor section of the Acorda website at www.acorda.com,
or you may use the link:
https://jpmorgan.metameetings.net/events/healthcare19/sessions/23912-acorda-therapeutics-inc/webcast
About Acorda Therapeutics
Acorda Therapeutics develops therapies to restore function and improve
the lives of people with neurological disorders. INBRIJA™ (levodopa
inhalation powder), an investigational inhaled formulation of levodopa
for symptoms of OFF periods for people with Parkinson’s on a
carbidopa/levodopa regimen, is under FDA review with a PDUFA date of
January 5, 2019. INBRIJA utilizes Acorda’s innovative ARCUS® pulmonary
delivery system, a technology platform designed to deliver medication
through inhalation. Acorda also markets the branded AMPYRA®
(dalfampridine) Extended Release Tablets, 10 mg.
Forward-Looking Statement
This press release includes forward-looking statements. All statements,
other than statements of historical facts, regarding management's
expectations, beliefs, goals, plans or prospects should be considered
forward-looking. These statements are subject to risks and uncertainties
that could cause actual results to differ materially, including: the
ability to realize the benefits anticipated from acquisitions, among
other reasons because acquired development programs are generally
subject to all the risks inherent in the drug development process and
our knowledge of the risks specifically relevant to acquired programs
generally improves over time; we may need to raise additional funds to
finance our operations and may not be able to do so on acceptable terms;
increasing competition and accompanying loss of revenues in the U.S.
from generic versions of Ampyra (dalfampridine) following our loss of
patent exclusivity; the risk of unfavorable results from future studies
of Inbrija (levodopa inhalation powder) or from our other research and
development programs, or any other acquired or in-licensed programs; we
may not be able to complete development of, obtain regulatory approval
for, or successfully market Inbrija or any other products under
development; risks associated with complex, regulated manufacturing
processes for pharmaceuticals, which could affect whether we have
sufficient commercial supply of Inbrija to meet market demand, if it
receives regulatory approval; third party payers (including governmental
agencies) may not reimburse for the use of Ampyra, Inbrija or our other
products at acceptable rates or at all and may impose restrictive prior
authorization requirements that limit or block prescriptions; the
occurrence of adverse safety events with our products; the outcome (by
judgment or settlement) and costs of legal, administrative or regulatory
proceedings, investigations or inspections, including, without
limitation, collective, representative or class action litigation;
competition; failure to protect our intellectual property, to defend
against the intellectual property claims of others or to obtain third
party intellectual property licenses needed for the commercialization of
our products; and failure to comply with regulatory requirements could
result in adverse action by regulatory agencies.
These and other risks are described in greater detail in our filings
with the Securities and Exchange Commission. We may not actually achieve
the goals or plans described in our forward-looking statements, and
investors should not place undue reliance on these statements.
Forward-looking statements made in this press release are made only as
of the date hereof, and we disclaim any intent or obligation to update
any forward-looking statements as a result of developments occurring
after the date of this press release.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20181219005039/en/
Felicia Vonella
(914) 326-5146
fvonella@acorda.com
Source: Acorda Therapeutics, Inc.